Literature DB >> 23126367

Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects.

Mikko T Holmberg1, Aleksi Tornio, Lotta Joutsi-Korhonen, Mikko Neuvonen, Pertti J Neuvonen, Riitta Lassila, Mikko Niemi, Janne T Backman.   

Abstract

AIM: This study examined the effects of grapefruit juice on the new P2Y12 inhibitor ticagrelor, which is a substrate of CYP3A4 and P-glycoprotein.
METHODS: In a randomized crossover study, 10 healthy volunteers ingested 200 ml of grapefruit juice or water thrice daily for 4 days. On day 3, they ingested a single 90 mg dose of ticagrelor.
RESULTS: Grapefruit juice increased ticagrelor geometric mean peak plasma concentration (Cmax ) to 165% (95% confidence interval 147, 184%) and area under the concentration-time curve (AUC(0,∞)) to 221% of control (95% confidence interval 200, 245%). The Cmax and AUC(0,34 h) (P < 0.05) but not the AUC(0,∞) of the active metabolite C12490XX were decreased significantly. Grapefruit juice had a minor effect on ticagrelor elimination half-life prolonging it from 6.7 to 7.2 h (P = 0.036). In good correlation with the elevated plasma ticagrelor concentrations, grapefruit juice enhanced the antiplatelet effect of ticagrelor, assessed with VerifyNow® and Multiplate® methods, and postponed the recovery of platelet reactivity.
CONCLUSIONS: Grapefruit juice increased ticagrelor exposure by more than two-fold, leading to an enhanced and prolonged ticagrelor antiplatelet effect. The grapefruit juice-ticagrelor interaction seems clinically important and indicates the significance of intestinal metabolism to ticagrelor pharmacokinetics.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23126367      PMCID: PMC3690107          DOI: 10.1111/bcp.12026

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  38 in total

Review 1.  Central role of the P2Y12 receptor in platelet activation.

Authors:  Robert T Dorsam; Satya P Kunapuli
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 2.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.

Authors:  Juergen Koessler; Anna L Kobsar; Mirjana S Rajkovic; Andreas Schafer; Ulrike Flierl; Stephanie Pfoertsch; Johann Bauersachs; Udo Steigerwald; Andreas R Rechner; Ulrich Walter
Journal:  Platelets       Date:  2010-09-27       Impact factor: 3.862

4.  In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.

Authors:  Diansong Zhou; Tommy B Andersson; Scott W Grimm
Journal:  Drug Metab Dispos       Date:  2010-12-22       Impact factor: 3.922

5.  Grapefruit juice enhances the exposure to oral oxycodone.

Authors:  Tuija H Nieminen; Nora M Hagelberg; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-10       Impact factor: 4.080

6.  Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.

Authors:  Renli Teng; Stuart Oliver; Martin A Hayes; Kathleen Butler
Journal:  Drug Metab Dispos       Date:  2010-06-15       Impact factor: 3.922

7.  Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.

Authors:  T Tapaninen; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2010-07-21       Impact factor: 6.875

Review 8.  Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides.

Authors:  David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2009-09-29       Impact factor: 3.126

9.  Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

Authors:  J J J VAN Giezen; L Nilsson; P Berntsson; B-M Wissing; F Giordanetto; W Tomlinson; P J Greasley
Journal:  J Thromb Haemost       Date:  2009-06-23       Impact factor: 5.824

Review 10.  Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.

Authors:  Eitan Abergel; Eugenia Nikolsky
Journal:  Vasc Health Risk Manag       Date:  2010-10-21
View more
  9 in total

Review 1.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Effect of grapefruit juice on the bioactivation of prasugrel.

Authors:  Mikko T Holmberg; Aleksi Tornio; Hanna Hyvärinen; Mikko Neuvonen; Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 3.  Phenolic Bioactives as Antiplatelet Aggregation Factors: The Pivotal Ingredients in Maintaining Cardiovascular Health.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Wissam Zam; Manoj Kumar; Susana M Cardoso; Olivia R Pereira; Adedayo O Ademiluyi; Oluwakemi Adeleke; Ana Catarina Moreira; Jelena Živković; Felipe Noriega; Seyed Abdulmajid Ayatollahi; Farzad Kobarfard; Mehrdad Faizi; Miquel Martorell; Natália Cruz-Martins; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Mohammed M Alshehri; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-08-17       Impact factor: 6.543

4.  Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.

Authors:  Khaled S Abdlekawy; Ahmed M Donia; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 5.  Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update.

Authors:  Renli Teng
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Authors:  Zhi-Yu Wang; Meng Chen; Ling-Ling Zhu; Lu-Shan Yu; Su Zeng; Mei-Xiang Xiang; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2015-03-19       Impact factor: 2.423

Review 7.  A Practical Perspective on the Use of Botanicals During the COVID-19 Pandemic: From Proven to Potential Interactions.

Authors:  Alexander Bertuccioli; Marco Cardinali; Francesco Di Pierro; Simone Magi; Giordano Zonzini
Journal:  J Med Food       Date:  2021-11-17       Impact factor: 2.786

Review 8.  Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

Authors:  Paul P Dobesh; Julie H Oestreich
Journal:  Pharmacotherapy       Date:  2014-08-28       Impact factor: 4.705

9.  Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada.

Authors:  Marie Lordkipanidzé; Guillaume Marquis-Gravel; Jean-François Tanguay; Shamir R Mehta; Derek Y F So
Journal:  CJC Open       Date:  2020-12-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.